Keywords
How to Cite
Abstract
Background Information: Vaccines are temperature-sensitive biological preparations, the proper range were cold chain period or 2-8 °C. The change of the temperature or cold chain breakdown might be effect to vaccines quality assurance.
Aim: The temperature data of Diphtheria-Tetanus-Pertussis and Hepatitis B vaccine, DPT- HB vaccine in fiscal year 2011-2012 were analyzed and aimed to find the factor that effected to vaccine cold chain system.
Method: Temperature data from health care units in 8 provinces collected by computerized data logger were analyzed by SPSS for window version 17.0 and Logtag analyzer program.
Result: From 322 health care units, most of data was reported from Chiang Rai province and collected from Primary Care Unit; PCU in both fiscal year. The period of time for recording of the data logger were very fluctuates. The highest number of data was reported in October, 2011 and in February, 2012. DPT-HB vaccine temperature had lower than 2°C at 86.9%, higher than 8°C at 90.4% in 2011, and lower than 2°C at 78.5%, higher than 8°C at 92.5% in 2012. Type of health care unit did not effect to vaccine’s temperature monitor but seasonal had significant effect.
Conclusion: Type of health care unit did not effect to vaccine’s temperature control. Seasonal had significant effect to vaccine’s temperature control. Based on the study results, adequate equipment, provide training and supervision about new and current computerize data logger were recommended to support to maximize the efficacy and effectiveness of vaccine and cold chain monitoring in health care unit.
References
Department of Immunization, Vaccines and Other Biologicals, World Health Organization. Cold chain, vaccines and safe-injection equipment management. Geneva: WHO 2008.
World Health Organization. The effects of freezing of the appearance, potency and toxicity on adsorbed and unabsorbed DTP vaccines. Weekly Epidemiological Record 1980; 55: 385-392.
Tharmaphornpilas P, Yoocharoan P, Prempree P, Youngpairoj S, Sriprasert P, Vitek CR. Diphtheria in Thailand in the 1990s. J Infect Dis 2001; 184: 1035-40. https://doi.org/10.1086/323453
American Academy of Pediatrics. Tetanus. In: Pickering LK, Baker CJ, Long SS, Kimberlin DW, editorss. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics 2009; pp. 555-60.
Centers for Disease Control and Prevention (CDC). Final reports of internationally notifiablediseases. MMWR Morb Mortal Wkly Rep 2010; 59: 1025,1027-39.
Bisgard KM, Rhodes P, Connelly BL, Bi D, Hahn C, Patrick S, et al. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001. Pediatrics 2005; 116: e285-94. https://doi.org/10.1542/peds.2004-2759
Casey JR, Pichichero ME. Acellular pertussis vaccine safety and efficacy in children, adolescents and adults. Drugs 2005; 65: 1367-89. https://doi.org/10.2165/00003495-200565100-00005
Kosuwon P, Warachit B, Hutagalung Y, Borkird T, Kosalaraksa P, Bock HL, et al. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (dTpa) administered as a booster to 4-6 year-old children primed with four doses of whole-cell pertussis vaccine. Vaccine 2003; 21: 4194-200. https://doi.org/10.1016/S0264-410X(03)00496-1
Sänger R, Behre U, Krause KH, Loch HP, Soemantri P, Herrmann D, et al. Booster vaccination and 1-year follow-up of 4-8-year-old children with a reduced-antigen-content dTpa-IPV vaccine. Eur J Pediatr 2007; 166: 1229-36. https://doi.org/10.1007/s00431-006-0403-x
Langley JM, Predy G, Guasparini R, Law B, Diaz-Mitoma F, Whitstitt P, et al. An adolescent-adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine. Vaccine 2007; 25: 1121-5. https://doi.org/10.1016/j.vaccine.2006.09.053
Meyer CU, Habermehl P, Knuf M, Hoet B, Wolter J, Zepp F. Immunogenicity and reactogenicity of acellular pertussis booster vaccines in children: standard pediatric versus a reduced-antigen content formulation. Hum Vaccin 2008; 4: 203-9. https://doi.org/10.4161/hv.4.3.5290
Scheifele DW, Halperin SA, Ochnio JJ, Ferguson AC, Skowronski DM. A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial. Pediatr Infect Dis J 2005; 24: 1059-66. https://doi.org/10.1097/01.inf.0000190028.96152.46
Bailleux F, Coudeville L, Kolenc-Saban A, Bevilacqua J, Barreto L, André P. Predicted long-term persistence of pertussis antibodies in adolescents after an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine, based on mathematical modeling and 5-year observed data. Vaccine 2008; 26: 3903-8. https://doi.org/10.1016/j.vaccine.2008.04.089
Techathawat S, Varinsathien P, Rasdjarmrearnsook A, Tharmaphornpilas P. Exposure to heat and freezing in the vaccine cold chain in Thailand. Vaccine 2007; 1328-33. https://doi.org/10.1016/j.vaccine.2006.09.092
Hilary Briggs SI. Weak link in vaccine cold chain. BMJ 1993; 306: 557-8. https://doi.org/10.1136/bmj.306.6877.557
Nelson C, Froes p, Dyck AMV, Chavarria J, Boda E, Coca A, et al. Monitoring temperatures in the vaccine cold chain in Bolivia. Vaccine 2007; 433-7. https://doi.org/10.1016/j.vaccine.2006.08.017
Chen D, Tyagi A, Carpenter J, Perkins S, Sylvester D, Guy M, et al. Characterization of the freeze sensitivity of a hepatitis B vaccine. Human Vaccines 2009; 5: 26-32. https://doi.org/10.4161/hv.5.1.6494
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2019 Kannika Thiankhanithikun , Nopphadol Chalortham , Siriporn Wohbah